The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Subscribe To Our Newsletter & Stay Updated
